Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

NetScientific PLC focused on “execution, execution and execution”

Biomedical and healthcare incubator NetScientific PLC (LON:NSCI) had a busy first half to the year, focusing on “execution, execution, execution”, according to chief executive officer François Martelet.
Backed by its world class scientific advisory boards, the investment company’s emphasis has been on accelerating its core portfolio companies - Wanda, Vortex Biosciences, Glycotest and ProAxsis - towards the commercialisation stage. That will set them up nicely for time when external funding will be needed to capitalise on the market opportunities.
ProAxsis is already on the cusp of fund-raising, and will seek external backers before the end of the year while Wanda, which now has an experienced CEO on board, also plans to seek external funding to capitalise on the significant opportunities in the digital healthcare space.
Martelet said the second half is set to be just as busy for those companies, and as they emerge from the development stage Martelet said the company would be looking to replenish the pipeline.
“We are certainly looking at organic growth … but we are looking at game changing technologies in the UK, in Europe and in the US as well to achieve that goal.”

 
Meet Tower Resources PLC, Arc Minerals Limited, Carbon Tracker and Tekcapital PLC at our event, London , 31 May 2018. Register here »
View full NSCI profile View Profile

Netscientific PLC Timeline

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use